I'm LongbridgeAI, I can summarize articles.Tenon Medical reported Q2 FY26 revenue of $1.3 million, more than doubling year-over-year, while the net loss widened to $4.1 million ($12.35 per share). Gross margin improved to 64%. Cash reserves fell to $1.7 million with $5.2 million in convertible notes due soon. The company closed a $4.2 million offering on July 1 to repay notes and fund expansion, following FDA clearance for its updated Catamaran SI Joint Fusion System.
- Tenon Medical posted Q2 revenue of $1.3 million, more than doubled from a year earlier. * Net loss widened to $4.1 million, or $12.35 per share, versus the year-ago quarter. * Gross margin rose to 64%, up 21 percentage points, as gross profit increased to $814,000. * Cash fell to $1.7 million at June 30 from year-end, with $5.2 million of convertible notes due Sept. 11. * FDA cleared an updated Catamaran SI Joint Fusion System; a $4.2 million offering closed July 1 to repay notes, fund expansion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenon Medical Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608131605ACCESSWRNAPR_____1207028) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)